RYTM Sells Off Hard After Earnings as Options Signal Unusual Bull Confidence

Rhythm Pharmaceuticals dropped 7.5% on November 3 and is down 6.2% on the week, the sharpest move in months, yet options positioning tells a strikingly different story from the price action.

The options signal is the most unusual element of this setup. Traders appear far more bullish than the selloff implies. The put/call ratio collapsed to 0.39 on November 3, nearly three standard deviations below its 20-day mean of 0.52, the lowest relative reading in the past year. That is an extreme skew toward calls, demand for upside exposure rather than downside protection, on a day when the stock fell sharply. Earnings landed on November 3, so the options positioning may reflect traders fading the dip rather than hedging into it. The 52-week range on the PCR runs from 0.08 to 0.64, and Tuesday's reading is well toward the bullish end of that spectrum.

Short interest, meanwhile, is elevated but easing. Bears hold roughly 15.7% of the free float, a level ORTEX classifies as high, but the position has been slowly unwinding. It has fallen about 0.5% over the past week and 2.4% over the past month, with FINRA's fortnightly settlement data putting the confirmed figure at just over 11 million shares on October 15. The borrowing market itself is entirely relaxed. Availability has actually widened following the selloff, now back to 1,421%, meaning there is roughly fourteen times as many shares available to borrow as are currently short. Cost to borrow is 0.42%, near its lowest level in six weeks. There is no sign of squeeze pressure. The bears are retreating gradually, not being forced out.

The Street remains predominantly bullish despite trimming targets after results. Needham cut its price target from $130 to $114 while keeping its Buy rating, a signal of recalibrated but maintained confidence. Citizens moved the other direction, lifting its target from $160 to $166 on November 4 while holding its Market Outperform. JP Morgan shaved its Overweight target only fractionally to $145. The mean analyst target across the full coverage universe is $140.29, implying roughly 62% upside from the current price of $86.44. That gap is wide even by biotech standards. Deutsche Bank stands as the lone dissent, holding a Hold with a $120 target. The forward EPS estimate trend factor ranks in the 97th percentile across the ORTEX universe, meaning few stocks anywhere have seen a faster upward revision to earnings expectations. The recommendation divergence score also ranks in the 92nd percentile, reflecting how heavily weighted analyst opinion is toward bullish ratings.

The bull case rests on IMCIVREE's expanding reach. Japan approved the drug for acquired hypothalamic obesity in late August, adding a launch opportunity before year-end in a market RYTM estimates at 5,000 to 8,000 patients. The Phase 3 TRANSCEND trial delivered an 18.8% placebo-adjusted BMI reduction, a clinically meaningful figure. RM-718, the pipeline follow-on, showed an 11.6% mean BMI reduction at 16 weeks in early Phase 2 data with a cleaner side-effect profile on injection-site hyperpigmentation. Bears counter that Imcivree only began active US and EU commercialization in 2022, leaving the launch track record thin, and that GLP-1 giants carry substantially more commercial infrastructure. The long-term setmelanotide dependency also concentrates IP risk, with patent protection modeled through 2035 but subject to challenge.

Institutional flows through September add one more layer of interest. T. Rowe Price added 911,295 shares in the quarter, JP Morgan Asset Management added over a million shares, and State Street added 301,678. Those are meaningful additions from credible names, sitting alongside RA Capital's 13G position at 9.9% of the class as of February. No 13D activists are on the register. Insider activity is less encouraging: net insider sales over the 90 days through September 14 totalled roughly 295,000 shares and $32.5 million in value, though all trades by CEO David Meeker and CFO Hunter Smith were executed under pre-arranged 10b5-1 plans, reducing their signal value as conviction trades.

Correlated peers diverged sharply from RYTM this week. SRRK gained 3.5%, PRAX rose 4.8%, and DNLI added 1.2%, all while RYTM fell 6.2%. The divergence isolates the selloff as company-specific rather than sector-driven. The next earnings event is pencilled in for February 23, 2027, giving 111 days for the Japan launch data and any TRANSCEND follow-up readouts to either close or widen the gap between the $86 price and the $140 analyst consensus.